GlobeNewswire

ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain

Share

-EDELWEISS 3trial of Yselty®expected to report topline data as plannedin Q4:21-

GENEVA, Switzerland and BOSTON, MA – May4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it has completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty® for patients with moderate to severe endometriosis-associated pain (EAP). Enrollment completion is an important milestone, and data from the primary endpoint readout are expected in Q4 2021.

“Endometriosis is an emotionally and physically painful condition that affects approximately 176 million women worldwide and can be debilitating for many women. We continue to be in need of alternative treatment options that improve quality of life,” said Jacques Donnez, M.D., Ph.D., Distinguished Professor of Obstetrics and Gynecology at the Catholic University of Louvain, Belgium. “The Phase 2b EDELWEISS data underscored Yselty’s potential to address this critical unmet need while offering unique dosing options. Importantly, linzagolix 75mg dose significantly improved EAP symptoms at 12 weeks and these effects were maintained or increased at 24 weeks and 52 weeks, without clinically relevant decreases in bone mineral density. This is particularly encouraging, and I look forward to seeing additional informative data from the EDELWEISS 3 trial.”

EDELWEISS 3 (Europe and the US) is a randomized, double-blind, placebo-controlled, Phase 3 trial that enrolled 486 women with moderate to severe EAP. The study is designed to evaluate the long-term efficacy and safety of Yselty, with a co-primary endpoint of reduction in both dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at Month 3, along with stable or decreased use of analgesics for EAP. The study includes a 75 mg once-daily dose without hormonal ABT (1 mg estradiol / 0.5mg norethindrone acetate), and a 200 mg once-daily dose in combination with ABT. Subjects who complete the initial six-month treatment period will have the option to enter a six-month treatment extension, followed by a post-treatment follow-up. Additional information about this study can be found here.

“The clinical development of Yselty for our endometriosis indication is a key priority for ObsEva, and we are pleased that the pivotal Phase 3 EDELWEISS 3 trial has continued to progress as planned,” said Brian O’Callaghan, CEO of ObsEva. “This milestone reflects significant progress and builds on the encouraging data from our Phase 2b trial, which demonstrated sustained improvement in overall endometriosis symptoms. With enrollment now completed for our Phase 3 trial, we are one step closer to providing women with better long-term treatment options. We will continue to build on this momentum and look forward to sharing top-line results later this year.”

About Yselty®
Yselty® (linzagolix) is a novel, oral, once daily, GnRH receptor antagonist with a potentially best-in-class profile. Yselty is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed Yselty from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product.
Yselty® is a registered trademark owned by Kissei for use by ObsEva. Yselty® is not yet approved for use anywhere in the world. 

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

About Kissei
Kissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and Unmet Medical Needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia which is sold worldwide through its licensees. KLH-2109/OBE2109 is a new chemical entity discovered by Kissei R&D.

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential therapeutic benefits and the clinical development of ObsEva’s product candidates, the potential for new indications for  any of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA, the timing of and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, the results of interactions with regulatory authorities and the potential to raise additional funds or enter into strategic partnerships in the future. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ACAMS’ ‘Virtual Europe’ Conference Offers Roadmap on Financial Crime Fight with Guidance from More than 80 Leading Compliance Experts11.5.2021 12:00:00 CEST | Press release

European regulators, senior industry executive and thought leaders to outline practical compliance steps for detecting and deterring financial crime, identifying the proceeds of corruption, fighting the illegal wildlife trade, tracing cryptocurrency transactions and deploying new technological tools LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- As part of its ongoing effort to facilitate dialogue between private-sector compliance professionals and policy makers , ACAMS will host a three-day training and networking event for its Virtual Europe conference. Beginning May 18, attendees of this fully virtual gathering will learn about anti-financial crime (AFC) best practices and emerging financial-crime threats from senior supervisory officials and other subject-matter experts, including representatives from the European Commission, European Central Bank, MONEYVAL, the United Nations Office on Drugs and Crime, World Bank, the central bank of the Netherlands, Latvia’s Financial Intelligence Unit

Kommuniké från årsstämman i Acarix11.5.2021 11:50:00 CEST | Pressemelding

Kommuniké från årsstämman i Acarix Årsstämman 2021 i Acarix AB ("Acarix" eller "Bolaget") hölls idag den 11 maj 2021 varvid aktieägarna fattade följande beslut. Med anledning av den pågående coronapandemin genomfördes stämman enbart genom poströstning, utan fysiskt deltagande. Fastställande av resultat- och balansräkningen Årsstämman beslutade att fastställa resultaträkningen och balansräkningen i Acarix samt koncernresultaträkningen och koncernbalansräkningen. Vinstdisposition Årsstämman beslutade att ingen utdelning skulle utgå till aktieägarna samt att tidigare balanserade medel, inklusive överkursfond samt årets resultat balanseras i ny räkning. Ansvarsfrihet Styrelsens ledamöter och den verkställande direktören beviljades ansvarsfrihet för verksamhetsåret 2020. Val av styrelse och revisor samt arvodering Årsstämman beslutade, i enlighet med valberedningens förslag, att styrelsen ska bestå av fyra ledamöter utan styrelsesuppleanter. Det beslutades vidare att Bolaget ska ha ett regi

Announcement from Acarix's annual general meeting11.5.2021 11:50:00 CEST | Press release

Announcement from Acarix's annual general meeting The annual general meeting 2021 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 2021 and the following resolutions were passed by the meeting. Due to the ongoing corona pandemic, the AGM was carried out through postal voting only, without physical presence. Adoption of the income statement and the balance sheet The AGM resolved to adopt the income statement and the balance sheet in Acarix and the consolidated income statement and the consolidated balance sheet. Allocation of profit The AGM resolved not to pay any dividend to the shareholders and that the previously accrued profits, including the share premium account and year result would be carried forward. Discharge from liability The board of directors and the CEO were discharged from liability for the financial year 2020. Election of the board of directors, auditor and remuneration The AGM resolved, in accordance with the nomination committee's proposal tha

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS11.5.2021 11:10:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-05-11Loan2206 Coupon0.25 %ISIN-codeSE0009269418Maturity2022-06-01 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln4,850 Volume bought, SEK mln1,000 Number of bids7 Number of accepted bids3 Average yield-0.107 %Lowest accepted yield-0.114 %Highest yield-0.104 %% accepted at lowest yield 25.00 Auction date2021-05-11Loan2311 Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,802 Volume bought, SEK mln1,000 Number of bids6 Number of accepted bids2 Average yield0.008 %Lowest accepted yield0.006 %Highest yield0.011 %% accepted at lowest yield 51.50 Auction date2021-05-11Loan2611Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln750 +/- 300 Volume offered, SEK mln3,450 Volume bought, SEK mln750 Number of bids7 Number of accepted bids1 Average yield0.428 %Lowest accepted yield0.428 %Highest yield0.428 %% accepted at lowes

Report from the Annual General Meeting of Auriant Mining AB (publ) held on 11 May 202111.5.2021 10:36:04 CEST | Press release

Auriant Mining AB (publ) held its Annual General Meeting on Tuesday, 11 May 2021. In order to mitigate the spread of Covid-19, the Annual General Meeting was conducted by advance voting only, on the basis of temporary statutory rules. The main resolutions passed at the meeting were as follows. More detailed information about the contents of the resolutions may be obtained from the complete notice of the AGM and the complete proposals. The notice and complete proposals are available on the company’s website: www.auriant.com. Adoption of balance sheets and profit and loss accounts It was resolved at the meeting to adopt the profit and loss account and balance sheet, as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2020. Allocation regarding the company’s result In accordance with the board’s and the managing director’s proposal, it was resolved at the meeting that the company’s non-restricted equity of SEK -86,488,459 is carried fo

Kommuniké från Auriant Mining AB (publ):s årsstämma den 11 maj 202111.5.2021 10:36:04 CEST | Pressemelding

Auriant Mining AB (publ) höll under tisdagen den 11 maj 2021 sin årsstämma. För att motverka spridning av Covid-19 genomfördes årsstämman enbart genom förhandsröstning med stöd av tillfälliga lagregler . Följande huvudsakliga beslut fattades vid årsstämman. För mer detaljerad information om innehållet i besluten hänvisas till den fullständiga kallelsen till årsstämman och de fullständiga förslagen. Kallelse till årsstämman samt fullständiga förslag finns tillgängliga på bolagets hemsida, www.auriant.se. Fastställande av balans- och resultaträkningar Stämman beslutade att fastställa resultaträkningen och balansräkningen samt koncernresultat-räkningen och koncernbalansräkningen för räkenskapsåret 2020. Disposition av bolagets resultat Stämman beslutade, i enlighet med styrelsens och verkställande direktörens förslag, att bolagets fria egna kapital om -86 488 459 kronor balanseras i ny räkning och att ingen utdelning lämnas för räkenskapsåret. Ansvarsfrihet Stämman beviljade styrelseledam

Klövern - Meddelande om skriftligt förfarande11.5.2021 10:20:30 CEST | Pressemelding

Klövern AB (publ) (”Klövern”) har idag instruerat Nordic Trustee & Agency AB (publ) (”Agenten”), som agerar agent under Klöverns seniora säkerställda obligation som emitterades i oktober 2019 med ett belopp om 50 000 000 USD med ISIN NO0010866205 (”Obligationslånet”), att inleda ett skriftligt förfarande där Klövern ber om att obligationsinvesterarna röstar för att ändra vissa bestämmelser i villkoren för Obligationslånet. Klövern önskar ändra villkoren för Obligationslånet och emittera ytterligare 50 000 000 USD till ett fåtal investerare samt förlänga den tidigare löptiden som löper till den 15 oktober 2021 till att löpa till den 15 juli 2023. I samband med detta kommer bland annat lämnade säkerheter att utökas. Ett meddelande om skriftligt förfarande kommer att skickas till samtliga obligationsinnehavare den 11 maj 2021 i enlighet med villkoren för Obligationslånet. Det skriftliga förfarandet avslutas senast den 31 maj 2021. Kallelsen gällande skriftligt förfarande finns på Klöverns